Neurochemical effects of quetiapine in patients with bipolar mania: A proton magnetic resonance spectroscopy study

Journal of Clinical Psychopharmacology

Volumn 33, Issue 4, 2013, Pages 528-532

  Adler, Caleb M ^a,b   Delbello, Melissa P ^a   Weber, Wade A ^a   Jarvis, Kelly B ^a   Welge, Jeffrey ^a   Chu, Wen Jang ^b   Rummelhoff, Emily ^a   Kim, Mi Jung ^b   Lee, Jing Huei ^b   Strakowski, Stephen M ^a,b  

^a Division of Bipolar Disorders Research   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

bipolar disorder; MRS; quetiapine

Indexed keywords

N ACETYLASPARTIC ACID; QUETIAPINE;

ADULT; ANTERIOR CINGULATE; ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; MONOTHERAPY; NEUROCHEMISTRY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REMISSION; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; BIOLOGICAL MARKERS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; DIBENZOTHIAZEPINES; FEMALE; GYRUS CINGULI; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PREFRONTAL CORTEX; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879845151     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182905b77     Document Type: Article

References (33)

1. Murray CJL, Lopez AD. Global Burden of Disease. Cambridge: Harvard University Press; 1998.
2. Van der Velde CD. Effectiveness of lithium carbonate in the treatment of manic-depressive illness. Am J Psychiatry. 1970;127(3):345-351.
3. Carroll BJ. Prediction of treatment outcome with lithium. Arch Gen Psychiatry. 1979;36(8 Spec No):870-878.
4. Mander AJ. Clinical prediction of outcome and lithium response in bipolar affective disorder. J Affect Disord. 1986;11(1):35-41.
5. Maj M, Pirozzi R, Starace F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. J Affect Disord. 1989;17(3):237-241.
6. Glitz DA, Manji HK, Moore GJ. Mood disorders: treatment-induced changes in brain neurochemistry and structure. Semin Clin Neuropsychiatry. 2002;7(4):269-280.
7. Strakowski SM, Wilson DR, Tohen M, et al. Structural brain abnormalities in first-episode mania. Biol Psychiatry. 1993;33:602-609.
8. Bertolino A, Frye M, Callicott JH, et al. Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging. Biol Psychiatry. 2003; 53(10):906-913.
9. Cecil KM, DelBello MP, Morey R, et al. Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord. 2002;4(6):357-365.
10. Chang K, Adleman N, Dienes K, et al. Decreased N-acetylaspartate in children with familial bipolar disorder. Biol Psychiatry. 2003;53 (11):1059-1065.
11. Dager SR, Friedman SD, Parow A, et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry. 2004;61(5):450-458.
12. Davanzo P, Thomas MA, Yue K, et al. Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology. 2001; 24(4):359-369.
13. DelBello MP, Cecil KM, Adler CM, et al. Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology. 2006; 31(6):1264-1273.
14. Frey BN, Folgierini M, Nicoletti M, et al. A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania. Hum Psychopharmacol. 2005;20(2):133-139.
15. Hamakawa H, Kato T, Shioiri T, et al. Quantitative proton magnetic resonance spectroscopy of the bilateral frontal lobes in patients with bipolar disorder. Psychol Med. 1999;29(3):639-644.
16. Winsberg ME, Sachs N, Tate DL, et al. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol Psychiatry. 2000;47(6):475-481.
17. Atmaca M, Yildirim H, Ozdemir H, et al. Hippocampal 1H MRS in patients with bipolar disorder taking valproate versus valproate plus quetiapine. Psychol Med. 2007;37(1):121-129.
18. Brambilla P, Stanley JA, Nicoletti MA, et al. 1H magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in bipolar disorder patients. J Affect Disord. 2005;86(1):61-67.
19. Friedman SD, Dager SR, Parow A, et al. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biol Psychiatry. 2004;56(5):340-348.
20. Sharma R, Venkatasubramanian PN, Bárány M, et al. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res. 1992;8(1):43-49.
21. Silverstone PH, Wu RH, O'Donnell T, et al. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol. 2003;18(2):73-79.
22. Kim DJ, Lyoo IK, Yoon SJ, et al. Clinical response of quetiapine in rapid cycling manic bipolar patients and lactate level changes in proton magnetic resonance spectroscopy. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1182-1188.
23. Patel NC, Cecil KM, Strakowski SM, et al. Neurochemical alterations in adolescent bipolar depression: a proton magnetic resonance spectroscopy pilot study of the prefrontal cortex. J Child Adolesc Psychopharmacol. 2008;18(6):623-627.
24. Strakowski SM, Adler CM, Almeida J, et al. The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord. 2012;14(4):313-325.
25. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IVAxis I DisordersVPatient Edition (SCID-I/P). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1995.
26. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133: 429-435.
27. Lee JH, Garwood M, Menon R, et al. High contrast and fast three-dimensional magnetic resonance imaging at high fields. Magn Reson Med. 1995;34(3):308-312
28. Tkac I, Staruck Z, Choi IY, et al. In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med. 1999;41:649-656.
29. Provincher S. Estimation of metabolite concentration from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672-679.
30. Hetherington HP, Mason GF, Pan JW, et al. Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1T. Magn Reson Med. 1994;32(5):565-571.
31. Gallelli KA,Wagner CM, Karchemskiy A, et al. N-acetylaspartate levels in bipolar offspring with and at high-risk for bipolar disorder. Bipolar Disord. 2005;7(6):589-597.
32. Delbello MP, Strakowski SM. Neurochemical predictors of response to pharmacologic treatments for bipolar disorder. Curr Psychiatry Rep. 2004;6(6):466-472.
33. Deicken RF, Pegues MP, Anzalone S, et al. Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder. Am J Psychiatry. 2003;160(5):873-882.